Peptron, Inc. (KOSDAQ:087010)

South Korea flag South Korea · Delayed Price · Currency is KRW
285,000
+4,500 (1.60%)
At close: Dec 5, 2025
190.52%
Market Cap 6.65T
Revenue (ttm) 6.19B
Net Income (ttm) -14.19B
Shares Out 23.32M
EPS (ttm) -623.60
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 430,804
Average Volume 407,079
Open 277,500
Previous Close 280,500
Day's Range 264,000 - 288,000
52-Week Range 76,500 - 392,500
Beta 0.79
RSI 45.66
Earnings Date n/a

About Peptron

Peptron, Inc. engages in the development of peptide-based medicines. The company’s technologies include long acting; and SmartDepot, an ultrasonic spray drying technology for the preparation of sustained release injectable microsphere formulation of drug. It develops PAb 001 for cancer therapy; SR-Exenatide (PT320) for Parkinson’s and other neurodegenerative disease; SR-Octreotide for the treatment of acromegaly; and Dernak filler for bioequivalence. Peptron, Inc. was founded in 1997 and is headquartered in Daejeon, South Korea. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1997
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 087010
Full Company Profile

Financial Performance

In 2024, Peptron's revenue was 3.15 billion, a decrease of -5.68% compared to the previous year's 3.34 billion. Losses were -22.03 billion, 38.4% more than in 2023.

Financial Statements

News

There is no news available yet.